Pleural effusion in dasatinib-treated patients with chronic myeloid leukemia in chronic phase: Identification and management Journal Article

  


Authors: Cortes, J. E.; Jimenez, C. A.; Mauro, M. J.; Geyer, A.; Pinilla-Ibarz, J.; Smith, B. D.
Article Title: Pleural effusion in dasatinib-treated patients with chronic myeloid leukemia in chronic phase: Identification and management
Abstract: Dasatinib has demonstrated durable clinical responses in patients, both as first-line and subsequent lines of therapy. Dasatinib use can result in pleural effusion in some patients, occurring any time during treatment and commonly characterized as mild to moderate in severity. Early identification of symptoms is essential in the proper management of pleural effusion. Prompt confirmation of diagnosis and management of pleural effusion can minimize morbidity and maximize the ability to preserve long-term clinical benefits with dasatinib. Here, we provide guidance on early identification and management of dasatinib-related pleural effusion. © 2016 The Authors
Keywords: algorithms; tyrosine kinase inhibitor; fluid retention; adverse events; bcr-abl1
Journal Title: Clinical Lymphoma, Myeloma and Leukemia
Volume: 17
Issue: 2
ISSN: 2152-2650
Publisher: Elsevier Inc.  
Date Published: 2017-02-01
Start Page: 78
End Page: 82
Language: English
DOI: 10.1016/j.clml.2016.09.012
PROVIDER: scopus
PUBMED: 28082112
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85011636450&doi=10.1016%2fj.clml.2016.09.012&partnerID=40&md5=87d21272abf547347e5d3f60d6c67d3e
Notes: Review -- Export Date: 2 March 2017 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Michael John Mauro
    267 Mauro
  2. Alexander Iosif Geyer
    33 Geyer
Related MSK Work